What biomarker tests are recommended for Melanoma

Biomarker Testing for Melanoma

Based on the NCCN Guidelines for Patients: Melanoma (2025), here's what you should know about biomarker testing for melanoma:

Key Biomarkers Tested

BRAF Mutation Testing This is the primary biomarker tested for melanoma. BRAF mutations are changes in a specific gene that can cause normal skin cells to become cancerous. According to NCCN Guidelines, BRAF mutation testing should be performed on your melanoma tissue, particularly if:

• Your melanoma is stage 3 (regional disease) or stage 4 (metastatic/spread)
• You're being considered for targeted therapy options
• You have recurrent melanoma

Why this matters: If you have a BRAF V600 mutation, you may be eligible for targeted therapy drugs like dabrafenib/trametinib, which specifically attack cancer cells with this mutation.

When Testing Occurs

According to NCCN Guidelines, biomarker testing typically happens:

• At initial diagnosis - on your biopsy tissue when melanoma is first confirmed
• At recurrence - if your melanoma returns, your doctor may test again if not previously done
• Before treatment decisions - to help determine which treatment options are most appropriate for your specific cancer

Other Testing Considerations

The NCCN Guidelines also mention that genetic testing for hereditary melanoma risk may be recommended if:

• You have a CDKN2A mutation (also called p16INK4A or MTS1), which is the most common gene mutation associated with familial melanoma
• You have multiple family members with melanoma diagnoses
• Your doctor recommends genetic counseling

Clinical Decision-Making Context

Here's how doctors typically use this information:

Oncologists use biomarker results to understand which treatment pathways might work best for your specific cancer. A BRAF mutation opens up targeted therapy options, while patients without this mutation may be directed toward immunotherapy approaches (like checkpoint inhibitors such as nivolumab or pembrolizumab).

Questions to Ask Your Healthcare Team

1. Has my melanoma tissue been tested for BRAF mutations? If not, should it be?
2. What were my specific biomarker results, and what do they mean for my treatment options?
3. Do I need genetic testing to check for hereditary melanoma risk factors?
4. Based on my biomarker results, which treatment approaches do you recommend for my situation?
5. Will biomarker testing be repeated if my cancer recurs?

Important Reminder

Your oncologist will determine which biomarker tests are appropriate for YOUR specific case based on your melanoma stage, location, and other clinical factors. The presence or absence of a BRAF mutation doesn't determine your prognosis alone—your doctor considers the complete clinical picture when making treatment recommendations.

According to NCCN Guidelines, biomarker testing is a standard part of melanoma evaluation and helps guide personalized treatment decisions, but your care team will explain what your specific results mean for your individual situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.